Biotech firm Viking Therapeutics, developing obesity drug in trials, reports $49.6M Q2 loss, but has $900M cash & significant investor interest.

Viking Therapeutics, Inc. (VKTX) is a biotech firm focused on developing therapies for metabolic disorders, with a promising obesity drug in trials that could compete with major players like Novo Nordisk and Eli Lilly. Despite a net loss of $49.6 million in Q2, VKTX boasts over $900 million in cash and significant investor interest, with 50 hedge funds holding a combined stake of $479.1 million. Its oral drug formulation may offer a competitive edge in the market.

September 21, 2024
3 Articles